Watertown, United States, 2024-Mar-31 — /EPR Network/ — Biopharma PEG Scientific Inc., a pioneering biotechnology company based in Watertown, Massachusetts, is set to make a [read full press release…]
Watertown, MA, 2024-Jan-21 — /EPR Network/ — Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which [read full press release…]
Watertown, MA, 2023-Nov-19 — /EPR Network/ — Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the [read full press release…]
Watertown, MA, 2023-Oct-21 — /EPR Network/ — Biopharma PEG, a leading provider of innovative solutions for the pharmaceutical industry, is proud to announce an extensive [read full press release…]
Watertown, MA, 2023-Aug-21 — /EPR Network/ — Cholesterol, a derivative of cyclopentane polyhydrophenanthrene, is the main steroid compound in mammals. Most of the traditional cholesterol [read full press release…]
Watertown, MA, 2023-Jul-15 — /EPR Network/ — What is “click chemistry”? “Click Chemistry”, this is a literary name given to this kind of reaction by [read full press release…]
Watertown, MA, 2023-Jul-03 — /EPR Network/ —Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. The link between the antibody and linker is controlled by the coupling method, which determines the DAR value of the drug and affects the stability and PK characteristics of the ADC. The connection of Linker to the drug is controlled by a shearable/non-shearable technique that determines the properties of the active payload, the rate at which the payload is released, and affects the solubility, stability, and titer of the ADC. Optimization of Antibody: Development of new targets and dual antibody ADCs The selection of antibodies [read full press release…]
Watertown, MA, 2023-Mar-29 — /EPR Network/ — Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the [read full press release…]
Watertown, MA, 2023-Jan-29 — /EPR Network/ — Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody [read full press release…]
Watertown, MA, 2022-Nov-29 — /EPR Network/ — Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into [read full press release…]
Hunan Province, China, 2022-Nov-29 — /EPR Network/ — Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma [read full press release…]
Watertown, MA, 2022-Oct-26 — /EPR Network/ — Technological advances have re-established ADC as a viable treatment strategy for advanced solid tumors. ADCs targeting several tumor [read full press release…]
Watertown, MA, 2022-Oct-26 — /EPR Network/ — Antibody-drug conjugate (ADC) consists of linker, payload, and monoclonal antibody (mAb). It combines the advantages of high specific [read full press release…]
Watertown, MA, 2022-Jul-30 — /EPR Network/ — Most of the drugs currently in clinical use are based on small molecules and use the “occupancy-driven” mode [read full press release…]
Watertown, MA, 2022-Mar-29 — /EPR Network/ — Just one dose of a new nanoparticle-based COVID-19 vaccine is enough to generate an immune response in animals, and the [read full press release…]
Arlington, VA, 2022-Feb-27 — /EPR Network/ — Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in [read full press release…]
Watertown, MA, 2022-Jan-25 — /EPR Network/ — 3D printing (3DP) technology has been repurposed to apply to pharmaceutical development, in recent years it has been [read full press release…]
Watertown, MA, 2021-Dec-23 — /EPR Network/ — Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects [read full press release…]
Watertown, MA, 2021-Nov-24 — /EPR Network/ — A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells [read full press release…]
Philadelphia, Pennsylvania, 2021-Sep-28 — /EPR Network/ — Physician-scientists in the Cancer Center at Children’s Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached [read full press release…]
